Covid19 Primer

Title	Date	Topic	News	Relevance
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated Jill Maaske et al in frontiers in immunology (7.561) Source crossref_works_2020_03_25	Jan 13, 2023	Placebo-controlled & Randomized	0	0.9
A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection Amit Singla et al in plos one (3.24) Source crossref_works_2020_03_25	Jan 30, 2023	Placebo-controlled & Randomized	0	0.8
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial Claudia M. Denkinger et al in nature cancer Source crossref_works_2020_03_25	Dec 29, 2022	Placebo-controlled & Randomized	1	0.8
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19 Matthew W. McCarthy et al in jama (31.777) Source crossref_works_2020_03_25	Jan 12, 2023	Placebo-controlled & Randomized	0	0.8
Efficacy and safety of sofosbuvir in the treatment of SARS-CoV-2: an open label phase II trial Mostafa Alavi-Moghaddam et al in frontiers in emergency medicine Source crossref_works_2020_03_25	Jan 16, 2023	Placebo-controlled & Randomized	0	0.7
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019 Myron J Levin et al in clinical infectious diseases (9.079) Source crossref_works_2020_03_25	Nov 22, 2022	Placebo-controlled & Randomized	0	0.6
Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain Edward Burn et al in nature communications (14.919) Source crossref_works_2020_03_25	Nov 23, 2022	Placebo-controlled & Randomized	0	0.6
Post-Exposure Prophylaxis with SA58 (anti-COVID-19 monoclonal antibody) Nasal Spray for the prevention of symptomatic Coronavirus Disease 2019 in healthy adult workers: A randomized, single-blind, placebo-controlled clinical study Rui Song et al in medRxiv : the preprint server for health sciences Source crossref_works_2020_03_25 Preprint	Jan 03, 2023	Placebo-controlled & Randomized	0	0.6
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland—Evaluation of Antibody Concentrations Paweł Zapolnik et al in vaccines (4.422) Source crossref_works_2020_03_25	Dec 29, 2022	Placebo-controlled & Randomized	0	0.5
Photodynamic nasal SARS-CoV-2 decolonization shortens infectivity and influences specific T-Cell responses Alejandro Fernandez-Montero et al in frontiers in cellular and infection microbiology (5.293) Source crossref_works_2020_03_25	Jan 25, 2023	Placebo-controlled & Randomized	1	0.5